Users Of Left Ventricular Assist Devices Show Improving Survival Rates

Main Category: Medical Devices / Diagnostics
Also Included In: Cardiovascular / Cardiology;  Blood / Hematology
Article Date: 01 May 2008 - 2:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Despite the general success of left ventricular assist devices (LVADs) used in critically ill heart failure patients, implantation of these devices often leads to increased bleeding and a need for high-volume blood transfusions during and immediately after surgery. A new study published in Artificial Organs provides data suggesting that the incidence of these complications may be significantly reduced by way of a single plasma exchange before surgery.

Patients in need of LVAD implantation usually have an abnormal coagulation profile, which can increase the chances of hemorrhagic complications after surgery. To optimize the coagulation profiles of LVAD patients, and thereby reduce the risk of complications, the study suggests replacing 1 plasma volume using fresh frozen plasma as the substitution fluid prior to surgery.

According to this single-center study, a series of patients who underwent plasma exchange before LVAD implantation had notably better survival rates than those who did not. These results were consistent both 7 and 30 days after insertion.

"Given the relatively benign nature of this intervention and the low risk posed, we believe that plasma exchange may be considered a treatment option for these high-risk patients," says lead author Rajko Radovancevic, senior research scientist at the Texas Heart Institute.

----------------------------
Article adapted by Medical News Today from original press release.
----------------------------

Rajko Radovancevic, M.D., is a senior research scientist at the Texas Heart Institute in Houston.

Since 1977, Artificial Organs has been publishing original articles featuring the studies of design, performance, and evaluation of the biomaterials and devices for the international medical, scientific, and engineering communities involved in the research and clinical application of artificial organ development. Artificial Organs, published monthly, brings its readership the depth and breadth of the science and technology that continues to advance the Replacement, Recovery and Regeneration of organ systems. For more information, please visit http://www.blackwell-synergy.com/loi/aor.

Wiley-Blackwell was formed in February 2007 as a result of the acquisition of Blackwell Publishing Ltd. by John Wiley & Sons, Inc., and its merger with Wiley's Scientific, Technical, and Medical business. Together, the companies have created a global publishing business with deep strength in every major academic and professional field. Wiley-Blackwell publishes approximately 1,400 scholarly peer-reviewed journals and an extensive collection of books with global appeal. For more information on Wiley-Blackwell, please visit http://www.blackwellpublishing.com/ or http://interscience.wiley.com/.

Source: Sean Wagner
Wiley-Blackwell